Figure 3
Effects of PHNO (0.001, 0.01, 0.1 μg/3 μl/rat) and co-administration of PHNO (0.1 μg) with a D 2 receptor antagonist, raclopride (0.1 μg), on ME DOPAC/DA ratio (upper) and serum PRL (lower) level in OVX+E 2 rats in the morning. Data are expressed as mean ± SEM (n = 5–7 rats). *, p < 0.05, compared with respective control groups. #, p < 0.05; ##, p < 0.01 compared with the PHNO (0.1 μg)-injected group.